Bio-Rad Laboratories Share Holder Equity 2010-2024 | BIO.B

Bio-Rad Laboratories share holder equity for the quarter ending December 31, 2024 was $6.569B, a 24.85% decline year-over-year.

  • Bio-Rad Laboratories share holder equity for 2024 was $6.569B, a 24.85% decline from 2023.
  • Bio-Rad Laboratories share holder equity for 2023 was $8.741B, a 9.09% decline from 2022.
  • Bio-Rad Laboratories share holder equity for 2022 was $9.615B, a 29.74% decline from 2021.

Quarterly Chart

Click on chart icon to view chart
Click on table icon to view table

Quarterly - YOY Change

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table

Annual % Change

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B